Molecular Staging of Malignant Melanoma

Authors:
  • XWXiangning Wang
    Xiangning Wang
  • WLWeiguo Li
    Weiguo Li
  • EJEmmanuella Joseph
    Emmanuella Joseph
  • JMJane Messina
    Jane Messina
  • LGL. Frank Glass
    L. Frank Glass
  • RDRonald DeConti
    Ronald DeConti
  • CCC. Wayne Cruse
    C. Wayne Cruse
  • CBClaudia Berman
    Claudia Berman
  • NFNeil A. Fenske
    Neil A. Fenske
  • GLGary H. Lyman
    Gary H. Lyman
  • DRDouglas S. Reintgen
    Douglas S. Reintgen

Abstract
FOR MOST solid tumors, including colon, lung, and breast carcinoma, the most powerful predictor of patient survival is the status of the regional lymph nodes. Once nodal metastases develop, prognostic factors based on the primary tumor contribute little to the prediction of recurrence and overall survival. For patients with malignant melanoma, the 5-year survival decreases 40% with the development of nodal metastases. Therefore, appropriate emphasis should be placed on accurate nodal staging for melanoma patients.

This publication has 19 references indexed in Scilit: